Banca de DEFESA: WILLIAM NEVES OLIVEIRA

Uma banca de DEFESA de MESTRADO foi cadastrada pelo programa.
STUDENT : WILLIAM NEVES OLIVEIRA
DATE: 20/05/2022
TIME: 13:30
LOCAL: Videoconferência
TITLE:

PHARMACOTHERAPEUTIC FOLLOW-UP IN PATIENTS WITH TYPE 1 DIABETES MELLITUS NO SCOPE OF JUDICIALIZATION: A POSSIBILITY OF DIRECT COST OPTIMIZATION

KEY WORDS:

Pharmacotherapeutic follow-up; Type I Diabetes Mellitus; Insulin Analogues; Judicialization; Partial economic analysis; Description of costs

PAGES: 100
BIG AREA: Ciências da Saúde
AREA: Saúde Coletiva
SUMMARY:

Background: The management of judicial demands for acquisition of medicines represents a challenge for the finances several Brazilian municipalities. The medications for the treatment of Diabetes mellitus (DM), especially insulin analogues, stand out as the items most demanded to the judicialization. However, access through for lawsuits doesn´t ensure the promotion of Rational use of medicines (RUM). This scenario, pharmacotherapeutic follow-up is a clinically effective strategy for patients with DM, but economic studies on this theme and population group are still incipient. Aim: To evaluate the direct medical costs one year after of pharmacotherapeutic follow-up service in type 1 diabetes mellitus (T1DM) patients receiving insulin analogues through to lawsuits on perspective of Brazilian Unified Health System (SUS). Methods: A quasi-experimental single-arm study with analysis of direct medical costs of T1DM patients using insulin analogues via judicialization. T1DM patients receiving insulin analogues by judicial decisions in a medium-sized municipality participated in the study. The pharmacotherapeutic follow-up was conducted according the Pharmacotherapy workup (PW) adapted method. Data were collected one year before the beginning of the intervention (baseline) and one year after its beginning (follow-up), using electronic medical records, hospital admission authorization, and data collected during the pharmacotherapeutic follow-up. Direct medical costs before and after pharmacotherapeutic follow-up were described, and the cost difference (followup - baseline) per patient was calculated. The time horizon set for the analysis was one year. Costs were adjusted to the year 2022, when earlier values were collected. Sensitivity analysis was performed to measure influence of the difference of each cost variable between pharmacotherapeutic follow-up and baseline on the total cost difference. Results: 28 patients completed all stages of the study. After pharmacotherapeutic follow-up, the total difference in direct medical costs was -R$19,274.16 and per patient was -R$688.36 (↓18.37%). Sensitivity analysis has shown 33.4% chance of the pharmacotherapeutic follow-up to reduce cost when compared to baseline. Conclusion: The findings suggest wich pharmacotherapeutic follow-up can reduce direct medical costs in SUS perspective of T1DM patients receiving medications through to lawsuits.

BANKING MEMBERS:
Presidente - 1039964 - ANDRE DE OLIVEIRA BALDONI
Externo à Instituição - LEONARDO RÉGIS LEIRA PEREIRA - USP
Externa ao Programa - 1296968 - MARIANA LINHARES PEREIRA
Externa à Instituição - PATRÍCIA MELO AGUIAR - USP